Moderna Stock

Moderna P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna (MRNA) as of Aug 3, 2026 is -7.99. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -4.07 — a change of 96.37% (lower).

P/FCF

-7.99

YoY

96.37%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna is 2026 -7.99 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna was 2025 -4.07 . It decreases by 96.37% lower compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna is -7.99 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Moderna changed from -4.07 to -7.99, representing a 96.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Moderna since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna